



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 18TH APRIL 2018 AT
12.30pm**

**IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chair)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T MacKenzie (TM)	GP, EL CCG

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
Dr S Perera	Consultant Paediatrician, ELHT (for item 2018/052)

2018/060: APOLOGIES:

Dr Y Naheed (YN)	GP, EL CCG
Dr P Shukla	GP, BwD CCG

2018/061: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2018/062: MINUTES OF MARCH MEETING:

Accepted as a correct record.

2018/063: MATTERS ARISING:

2017/137: LMMG Recommendations (from Sept) Vitamin D Position Statement –

The ELMMB guidance on Vitamin D flow chart has been amended to match with an amendment with respect to the timing of the Vitamin D assay. Some minor clarifications are also required, including: monitor at 1 month to be added after loading dose; monitor PTH if calcium is raised; include 400 units on PIL rather than leaving a space to be completed. The appendices are to be added to website as separate documents for easy access. The amendments to be made and document uploaded to website.

2018/040: Homely Remedies Policy – updated draft to be shared - deferred to next meeting.

2018/050: Wound Care Formulary – Hosiery Kits – the made to measure items are more costly than the standard kits and should only be used in exceptional circumstances. This information needs to be stipulated in formulary.

Deferred Item:

2018/052 LMMG RECOMMENDATIONS (from Feb LMMG)

Melatonin guidelines

Dr S Perera, Consultant Paediatrician, in attendance for this item.

The LMMG recommended the guideline produced by Lancashire Care FT for use of melatonin in children and adolescents for the management of sleep disturbance associated with Attention Deficit Hyperactivity Disorder (ADHD). This guideline recommends melatonin MR (circadin®) as the preparation.

An ELHT guideline has been produced for use by paediatric neurodevelopmental services for a wider group of patients and recommends melatonin immediate release (unlicensed) preparation.

Concern was raised with the limited evidence for melatonin use, how it is monitored and how the benefits are measured. The use of sleep diaries, benefits to patients and families, and trials off treatment were discussed.

It was agreed that Dr Perera would include the information on beneficial response on page 6 of the LCFT guidance in the ELHT guidance and bring back to ELMMB.

Resolved: ELHT melatonin guideline to be amended and brought back to ELMMB.

2018/064: NEW (UNLICENSED) PRODUCT REQUEST - OTOCOMB® OINTMENT

Otocomb® ointment requested by Mr Narayan, ENT Consultant, for otitis externa, administration by ENT doctors and for packing of external auditory canal in theatre. The product is equivalent to Triadcortyl, used prior to its discontinuation. It contains an antifungal which is not included in Synalar C. Approved for use by ENT to replace Synalar C and allocated a red traffic light.

Resolved: Otocomb® approved for formulary inclusion for ENT use.

Traffic Light: RED

2018/065: NEW PRODUCT REQUEST - CILODEX® EAR DROPS

Cilodex® ear drops requested by Mr Narayan, ENT Consultant, for otitis externa, and otitis media when tympanostomy tube in situ. The product contains ciprofloxacin and dexamethasone and would replace using unlicensed ciprofloxacin eye drops in the ear together with steroid ear drops. Approved for use by ENT to and allocated a red traffic light.

Resolved: Cilodex® approved for formulary inclusion for ENT use.

Traffic Light: RED

2018/066: NEW PRODUCT REQUEST - MYDRIASERT®

Mydriaser® requested by Mr Fernando, Ophthalmologist, for pre-operative mydriasis for diagnostic use. The product is an ophthalmic insert containing tropicamide and phenylephrine. Product is more expensive than mydriatic eye drops but reduces nursing time. Approved for use clinically by ophthalmology and allocated a red traffic light. Division to confirm there is financial sign off before it is introduced.

Resolved: Mydriaser® approved clinically for formulary inclusion for ophthalmology use – financial approval required by ELHT

Traffic Light: RED

2018/067: NEW PRODUCT REQUEST – DUPILUMAB

Dupilumab for severe atopic dermatitis is requested, on an access scheme, in advance of NICE recommendation for a patient who has failed all conventional treatments and requires urgent treatment. ELMMB supported use for one patient. Dupilumab remains non formulary.

Resolved: Dupilumab use for one patient in advance of NICE supported.

2018/068: NEW PRODUCT REQUEST – THICK AND EASY CLEAR

A working group of speech and language therapists & dieticians from hospital and community have reviewed available products for thickening foods. They recommend that Thick and Easy Clear is used as first line thickener across East Lancs. ELMMB accepted this recommendation and Thick and easy Clear to be included on relevant formulary.

Resolved: Thick and Easy Clear to be used as first line thickener.

2018/069: LMMG CONSULTATIONS (for May LMMG)

Lisdexamphetamine traffic light change – comments received from psychiatrists in child & adolescent services support the change to amber traffic light.

Resolved: Comments to be sent to LMMG

2018/070: LMMG RECOMMENDATIONS (from Mar LMMG)

New medicine recommendation – Trelegy Ellipta®

Product does not fit with ELHE guidance therefore not recommended for use in ELHE.

Traffic light: Black

LMWH Summary prescribing guidance - updated

ELHE guideline will continue to be used locally. LMMG guidance to be included on website for information and reference for out of area patients.

Psoriasis biologics Pathway - updated

LMMG position statement accepted as written for ELHE.

2018/071: FORMULARY UPDATES

Doxycycline dispersible tablets – to be added to formulary for patients with swallowing difficulties when doxycycline is the recommended antibiotic.

Traffic light: Green

Resolved: Formulary to be updated as above

2018/072: COVERT MEDICATION GUIDANCE - UPDATED

The guidance document for use by care providers has been updated. The ELMMB logo is to be added. Accepted for use in ELHE.

Resolved: Covert Medication Guidance for Care Providers accepted.

2018/073: RIFAXAMIN – GUIDELINES FOR PRESCRIBING

CCGs appear to be seeing an increase in numbers of patients being prescribed Rifaxamin. The proposed guideline that has been adapted from another area was shared with ELMMB. It was agreed that this would be shared with the directorate pharmacist and gastroenterology directorate for their comments, to include advice on: use with/without lactulose; recommendations following one/recurrent episodes; and stop date.

Action: Rifaxamin proposed guidelines to be discussed with gastroenterology.

2018/057: NICE RECOMMENDATIONS (from Mar)

Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee [TAG 508] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer [TAG 509] is recommended as an option by NICE. Approved in line with NICE.

NHSE Cancer Drugs Fund

Traffic Light: RED

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TAG 510) is recommended as an option by NICE. Approved in line with NICE.
NHSE Cancer Drugs Fund **Traffic Light: RED**

Brodalumab for treating moderate to severe plaque psoriasis [TAG 511] is recommended as an option by NICE. Approved in line with NICE.
CCG Commissioned – Blueteq form required **Traffic Light: RED**

Tivozanib for treating advanced renal cell carcinoma (TAG 512) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Obinutuzumab for untreated advanced follicular lymphoma (TAG 513) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Regorafenib for previously treated advanced hepatocellular carcinoma (TAG 514) is NOT recommended by NICE. **Traffic Light: Black**

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TAG 515) is NOT recommended by NICE. **Traffic Light: Black**

Cabozantinib for treating medullary thyroid cancer (TAG 516) is recommended as an option by NICE. Approved in line with NICE.
NHSE Cancer Drugs Fund **Traffic Light: RED**

STANDING ITEMS

2018/075: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Mar 2018

Minutes acknowledged

Item 2018/055 use of lidocaine & ketamine is in private hospital so will not be picked up when secondary care look at.

2018/076: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Dec 2017

Minutes acknowledged

2018/077: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Mar 2018

Minutes acknowledged

Item 2018/01.01b Request for Linezolid to be changed from red to Amber traffic light as occasionally longer term treatment is required. Use would be on microbiology advice.
ELMMB agreed to change Linezolid tablets to Amber. **Traffic light: Amber**

DATE OF NEXT MEETING – Wednesday 16TH May 2018 12.30pm, Seminar Room 6, Learning & Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 18TH APRIL 2018

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2018/040	Homely Remedies Policy – review	LR	May 18
2018/052	LMMG Recommendations (from Feb LMMG) Melatonin guidelines – ELHT guideline to include beneficial response information from LCFT guidance.	Dr Perera	May 18
2018/073	Rifaxamin – Guidelines for Prescribing – to be discussed with gastroenterology directorate	Directorate pharmacist /AG/VG	May 18